Evidence map›Paper›PMID 25688402›Full record

ArticleNature reviews. Cancer2014

Mining the genomes of exceptional responders.

David K Chang, Sean M Grimmond, T R Jeffry Evans, Andrew V Biankin

Abstract read
PubMed Publisher
In one paragraph

Article in Nature reviews. Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Identification of a RAS-activatingClinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  2. Article
  3. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine.Annals of oncology : official journal of the European Society for Medical Oncology · 2021
    Review
  4. Article
  5. Review
  6. Molecular subtypes of pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2019
    Review
  7. Review
  8. Article
  9. Article
  10. Hippo pathway mediates resistance to cytotoxic drugs.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

David K ChangWolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garsube Estate, Switchback Road, Bearsden Glasgow, Scotland G61 1BD, UK; The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, 364 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia.
Sean M GrimmondWolfson Wohl Cancer Research Centre, Insitute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, Scotland G61 1BD, UK; Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, 4067 Brisbane, Queensland, Australia.
T R Jeffry EvansWolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, Scotland G61 1BD, UK.
Andrew V BiankinWolfson Wohl Cancer Research Centre, Insitute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Bearsden, Glasgow, Scotland G61 1BD, UK; The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, 364 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Australia. andrew.biankin@glasgow.ac.uk

Funding

Cancer Research UK 11650
6 · The paper itself

Abstract

The National Cancer Institute of the United States recently announced a major new initiative in understanding the genomes or, more broadly, the molecular phenotypes of exceptional responders. What can we expect to learn from exceptional responders? What are the potential benefits, and how do we approach studying them?

Indexed as

Molecular Targeted TherapyDrug Resistance, NeoplasmGenomeHumansNeoplasmsPhenotypeTreatment Outcome

Identifiers

PMID25688402

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.